Latest CSL Limited Stories
-- Leading-edge science at the core of $250 million expansion to drive long-term growth in promising bleeding disorders portfolio KING OF PRUSSIA, Pa., May 9, 2014 /PRNewswire/
KING OF PRUSSIA, Pa., May 2, 2014 /PRNewswire/ -- CSL Behring today announced that the first patient has been enrolled
LONDON, April 29, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:
Participation in innovative public-private collaboration helps improve vaccination infrastructure, expand patient reach in partner countries KING OF PRUSSIA, Pa., April 28, 2014 /PRNewswire/
Donated coagulation factor supports WFH Global Alliance for Progress program KING OF PRUSSIA, Pa., April 17, 2014 /PRNewswire/ --
KING OF PRUSSIA, Pa., March 24, 2014 /PRNewswire/ -- Navigating the complexities of the Affordable Healthcare Act (ACA) can be challenging, particularly where patients with chronic medical disorders
Analysis also reveals decrease in emergency room visits and hospitalizations SAN DIEGO, March 1, 2014 /PRNewswire/ -- Findings announced by CSL Behring today show that current hereditary
bioCSL Inc. initiates 2014-15 season pre-booking for AFLURIA® (Influenza Vaccine) KING OF PRUSSIA, Pa., Feb.
DUBLIN, February 26, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/jnwqq6/h1n1_vaccines) has announced the addition of the "H1N1
- An aromatic woolly plant (Origanum dictamnus) native to Crete, formerly believed to have magical powers.